Related Experiment Video
Updated: Jun 18, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Neuroprotective Effects Exerted by a Combination of Selected Lactic Acid Bacteria in a Mouse Parkinsonism Model under
Daiana Pérez Visñuk1, Jean Guy LeBlanc2, Alejandra de Moreno de LeBlanc3
1Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, San Miguel de Tucumán,, T4000ILC, Tucumán, Argentina.
Abstract:
Alterations of the microbiota-gut-brain axis has been associated with intestinal and neuronal inflammation in Parkinson's disease (PD). The aim of this work was to study some mechanisms associated with the neuroprotective effect of a combination (MIX) of lactic acid bacteria (LAB) composed by Lactiplantibacillus plantarum CRL2130 (riboflavin overproducing strain), Streptococcus thermophilus CRL808 (folate producer strain), and CRL807 (immunomodulatory strain) in cell cultures and in a chronic model of parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in aged mice, and under levodopa-benserazide treatment. In vitro, N2a differentiated neurons were exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and treated with intracellular bacterial extracts or with conditioned media from BV-2 cells exposed to the bacterial extracts. In vivo, motor skills, tyrosine hydrolase (TH) in brain and cytokine concentrations in serum and in brain were evaluated. The study of the faecal microbiota and the histology of the small intestine was also performed. The results showed that the neuroprotective effect associated with LAB MIX administration did not interfere with levodopa-benserazide treatment. This effect could be associated with the antioxidant and immunomodulatory potential of the LAB selected in the MIX, and was associated with the significant improvement in the motor tests and a higher number of TH + cells in the brain. In addition, LAB MIX administration was associated with modulation of the immune response. LAB administration decreased intestinal damage with an increase in the villus length /crypt depth ratio. Finally, the administration of the LAB MIX in combination with levodopa-benserazide treatment was able to partially revert the intestinal dysbiosis observed in the model, showing greater similarity to the profiles of healthy controls, and highlighting the increase in the Lactobacillaceae family. Different mechanisms of action would be related to the protective effect of the selected LAB combination which has the potential to be evaluated as an adjuvant for conventional PD therapies.
Insights
This study shows a lactic acid bacteria (LAB) combination protects against Parkinson's disease (PD) neurodegeneration and improves motor function. The LAB mix, when combined with Levodopa-Benserazide, also helps restore gut health and does not interfere with PD treatment.
Area of Science:
- Neuroscience
- Microbiology
- Immunology
- Gastroenterology
Background:
- Alterations in the microbiota-gut-brain axis are linked to intestinal and neuronal inflammation in Parkinson's disease (PD).
- Existing PD treatments may benefit from adjunctive therapies targeting gut dysbiosis and neuroinflammation.
Purpose of the Study:
- To investigate the neuroprotective mechanisms of a specific lactic acid bacteria (LAB) combination (MIX) in Parkinson's disease models.
- To assess the efficacy of the LAB MIX as an adjuvant therapy alongside Levodopa-Benserazide treatment in a chronic parkinsonism model.
Main Methods:
- In vitro: Neuronal cells exposed to MPTP neurotoxin and treated with bacterial extracts or conditioned media.
- In vivo: Chronic MPTP-induced parkinsonism model in aged mice, evaluating motor skills, tyrosine hydroxylase (TH) expression, cytokine levels, fecal microbiota, and intestinal histology.
- Assessment of LAB MIX interaction with Levodopa-Benserazide treatment.
Main Results:
- The LAB MIX demonstrated neuroprotective effects, improving motor function and increasing TH+ cells in the brain.
- LAB MIX administration modulated immune responses, reduced intestinal damage, and increased the villus length/crypt depth ratio.
- Combined treatment with LAB MIX and Levodopa-Benserazide partially reversed intestinal dysbiosis, increasing Lactobacillaceae abundance, without interfering with Levodopa-Benserazide efficacy.
Conclusions:
- The selected LAB combination exhibits antioxidant and immunomodulatory properties, contributing to neuroprotection in Parkinson's disease.
- This LAB MIX shows potential as an adjuvant therapy for conventional PD treatments, improving both neurological and gastrointestinal symptoms.
- Further evaluation of this LAB combination is warranted for its therapeutic potential in Parkinson's disease management.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Neural Regulation

